Collagen Injection in Singapore

• PLLA requires reconstitution with sterile water before injection and post-injection massage to distribute the material evenly. Delivery is by fine needle or cannula depending on the treatment zone, with cannula often preferred where vascular proximity is a concern. Its collagen-stimulating effect builds gradually across the planned sessions rather than after a single visit.
• CaHA is supplied as a ready-to-use gel and is often selected when a patient wants some immediate contour alongside the longer-term biostimulatory effect, since the calcium microspheres provide a degree of structure at placement before the surrounding collagen response develops.
• PCL is typically delivered as a microsphere suspension in a gel carrier. It’s generally associated with a longer reported duration than PLLA or CaHA, though this varies by formulation strength, so the specific product used affects how long results are expected to last.

The synthetic polymer classes and regenerative options commonly evaluated in Singapore include PDLLA-based formulations and human-derived extracellular matrix materials. These modalities are detailed below.

A hybrid formulation combining poly-D,L-lactic acid with non-cross-linked hyaluronic acid. The hyaluronic acid component aims to provide temporary hydration and immediate tissue volume, while the PDLLA microparticles work over subsequent months to support natural collagen synthesis. This combination may be considered for patients seeking a subtle immediate effect alongside gradual structural support.

Placement is typically in the subcutaneous or periosteal plane depending on the target region (e.g. temples, cheeks, jawline, neck). While downtime is generally minimal, localised swelling or bruising may occur.

Poly-D,L-lactic acid suspended in a carboxymethylcellulose gel carrier, placed in the deep dermis. The carrier is the reason the appearance follows a distinctive four-stage pattern worth understanding before treatment: an immediate restoration of volume from the gel, then a partial loss as that carrier is absorbed over the following weeks, then a gradual rebuild as new collagen forms. Patients who are not told this in advance sometimes read the middle stage as the treatment failing, when it is the expected sequence.

It is used for volume loss in defined areas or across the face where laxity and dryness are both present. The session ends with a gentle massage to distribute the material evenly through the deeper dermal layers, which matters for reducing the risk of uneven distribution. Many patients resume normal activities within a couple of hours. Reported duration extends to around 24 months, and a course of roughly three sessions is common, subject to assessment.

Different in kind from the polymer-based options above. ECM Collagen Matrix uses micronised human acellular dermal matrix in powder form, reconstituted before injection. Rather than introducing a synthetic polymer that the body reacts to, it supplies extracellular matrix components derived from human skin, including collagen-supportive proteins, with the aim of supporting the skin’s structural framework directly.

Delivery is usually by blunt-tip micro-cannula, though a fine needle is used where appropriate. Depth is varied deliberately: superficial placement targets fine lines and surface texture, deeper placement addresses structural support. Treated areas include the cheeks, nasolabial folds, jawline, and under-eye region, as well as the neck, décolletage, and hands. It suits areas with thinning skin where skin quality matters more than added volume.

Two practical points separate it from the polymer biostimulators. Reported duration is around three to six months rather than one to two years, so maintenance is typically every four to six months, and the annual cost picture differs. And because the material is human-derived rather than synthetic, its regulatory classification is not the same as that of the PLLA, CaHA, PCL, and PDLLA devices, which is worth clarifying at consultation.